HundredX's strategy platform gives business leaders and their advisors an early view into the growth outlook for their business. We begin by gathering feedback on thousands of businesses provided by ‘The Crowd’ - actual customers representing the US Census.
Using advanced technologies, the feedback is transformed into decision-ready intelligence unmatched by legacy solutions. Our powerful suite of products – Scout, Strategist, and Summit – enables you to understand your growth outlook, get ahead of competitive trends, and make smarter decisions.
Scout
Competitive Insights needed to outperform
Stay on top of the evolving landscape with real-time insights across 90 industries and over 4,000 brands. Leverage more than 17M real customer experience summaries to understand what is driving future purchase intent, CSAT, brand relevance, NPS® and more.
Strategist
Predictive analytics to grow market share
Strategist redefines traditional strategy projects by delivering decision-ready, predictive insights to maximize market share. As your intelligent market guide, Strategist reveals future growth outlooks for thousands of brands, segments customers by what matters most to them, reveals your pricing power, and highlights the areas for investment to accelerate growth.
Summit
Transform your business
Elevate your organization with our exclusive end-to-end operating system that unifies the voice of your customers, employees, and stakeholders to drive growth. Summit combines expert advisory services, listening programs tailored to your needs and dedicated support to deliver customized insights that elevate your business for peak performance.
“HundredX has been one of the most impactful partners we’ve ever had at the Padres.”
Erik Greupner
CEO, San Diego Padres
Featured insights from The Crowd Report™
Consumers are navigating still-high prices with resilience. HundredX analysis, based on millions of pieces of customer feedback from July 2021 through April 2023 across 3,200+ companies, indicates inflation remains persistent, but consumers are cautiously hanging on. New Consumer Price Index (CPI) data shows prices increased 3.4% in April from a year ago, compared to 3.5% in March, which highlights a slight easing in inflation month-to-month. Still, HundredX data shows that consumers still feel negative about prices in general, pointing to inflation’s stickiness and consumer frustrations over the consistently high prices of everyday goods. Generally, we’ve seen that changes to HundredX’s Price favorability index are typically inversely correlated with movement in the CPI levels (i.e., inflation) reported by the US government.
Sure, lattes, mochaccinos, and cappuccinos are pricey, but they taste delicious. For many consumers, the great taste of coffee shop coffee made it worth the cost. But customers at Starbucks aren't so sure the tradeoff is worth it anymore. Examining more than 420,000 pieces of feedback across the Quick, Fast, Casual (QFC) industry, including over 21,000 on Starbucks, we find: Starbuck's Purchase Intent 1,2 is down 3% over the past six months, with most of that dip occurring over the past few months. By contrast, Dunkin' Donuts has remained within a tight range over the past six months, as did an average of other, smaller coffee chains. Customers increasingly see less value in Starbucks. Starbuck's Value perception 3 fell 5% over the past six months, compared to just 1% for Dunkin' Donuts. However, it also fell 5% for the average of the smaller coffee chains. Coffee drinkers feel significantly unhappier about Starbuck's quality and taste. Starbuck's Taste perception fell 4% over the past six months, while rising 1% for competitors. Likewise, its Quality perception dipped 3% over the same time period (and 8% over the year). Ultimately, Starbuck's perceived drop in taste is leading inflation-weary consumers to say they plan to spend less at the coffee chain, as the value just isn't as good.
Ozempic once dominated the headlines, but GLP-1 competitor Mounjaro is winning over customers. GLP-1 drugs, used for treating diabetes and aiding in weight loss, are relatively new on the market yet have surged in popularity over the last year. They're becoming so popular that J.P. Morgan estimates that 30 million people in the US may be using a GLP-1 drug by 2030. This statistic presents a significant potential for early drug creator Novo Nordisk (Ozempic, Wegovy), and perhaps an even bigger one for Eli Lilly (Mounjaro, Zepbound). HundredX data indicates Eli Lilly is in a position to win over Novo Nordisk as Mounjaro's Usage Intent widens against the competition. Ozempic may have name recognition, but customers feel more positively about Mounjaro's effectiveness and lifestyle impact, even if they aren't excited about its high price. Examining 1,500 pieces of customer feedback across Mounjaro, Ozempic, and Wegovy, we find: GLP-1 users increasingly say they plan to use Mounjaro more, and Ozempic less . Mounjaro’s Usage Intent is up 19% since July, Wegovy’s is up 3%, and Ozempic has stayed within a tight range. Customers feel Mounjaro is more effective than competing drugs, but it’s harder to get . Mounjaro outperforms other GLP-1 drugs in effectiveness, lifestyle impact, and side effects. However, customers dislike its cost and availably more than competitors.